Western blot and immunofluorescence (IF) assays revealed that PRMT5 knockdown elevated γ‐H2AX levels in CRC cells following CPT‐11 treatment (Figure 2J–N; Figure S3E, Supporting Information). Here, PRMT5 is linked to colorectal carcinoma.